Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to Immunotherapy

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318

Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity

Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Τακακι, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314

Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma

Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297

A new dawn for eosinophils in the tumour microenvironment

Grisaru‐Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 315

Eosinophils: The unsung heroes in cancer?

Varricchi, G., Galdiero, M. R., Loffredo, S., Lucarini, V., Marone, G., Mattei, F., Marone, G., & Schiavoni, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393134 · Cited by 288

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 249

Exploiting innate immunity for cancer immunotherapy

Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222

Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer

Ju, M., Bi, J., Wei, Q., Jiang, L., Guan, Q., Zhang, M., Song, X., Chen, T., Fan, J., Li, X., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa345 · Cited by 185

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma

Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., Liao, Y., Hediyeh-zadeh, S., Grisaru‐Tal, S., Louis, C., Huang, Q., Schreuder, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00943-z · Cited by 186

Eosinophils from A to Z

Gigon, L., Fettrelet, T., Yousefi, S., Simon, D., & Simon, H. (2023) · Allergy · doi:10.1111/all.15751 · Cited by 142

Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy

Grisaru‐Tal, S., Rothenberg, M. E., & Munitz, A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01291-2 · Cited by 131

Opposing roles of eosinophils in cancer

Simon, S. C. S., Utikal, J., & Umansky, V. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2255-4 · Cited by 128

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Warner, A. B., Brady, M. S., Coit, D. G., Callahan, M. K., Wolchok, J. D., Chapman, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1356 · Cited by 127

Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies

Nakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors

Simon, S. C. S., Hu, X., Panten, J., Grees, M., Renders, S., Thomas, D., Weber, R., Schulze, T. J., Utikal, J. S., & Umansky, V. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1727116 · Cited by 88

Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.

Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78

AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Jensen‐Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels‐Wells, T. R., Dombrowicz, D., Fiebiger, E., Gould, H. J., Irshad, S., Janda, J., et al. (2017) · Allergy · doi:10.1111/all.13311 · Cited by 76

Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy

Cheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 76

Nicotinamide inhibits melanoma in vitro and in vivo

Scatozza, F., Moschella, F., D’Arcangelo, D., Rossi, S., Tabolacci, C., Giampietri, C., Proietti, E., Facchiano, F., & Facchiano, A. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01719-3 · Cited by 68

Biomarkers to predict prognosis and response to checkpoint inhibitors

Yuasa, T., Masuda, H., Yamamoto, S., Numao, N., & Yonese, J. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1122-1 · Cited by 66

The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms

Frigerio, S., Lartey, D. A., D’Haens, G., & Grootjans, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312739 · Cited by 66

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61

CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Kunert, A., Basak, E. A., Hurkmans, D. P., Balcioglu, H. E., Klaver, Y., van Brakel, M., Oostvogels, A. A. M., Lamers, C. H. J., Bins, S., Koolen, S. L. W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0608-y · Cited by 59

Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies

Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 60

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59

Cancer Immunoediting by Innate Lymphoid Cells

Wagner, M., & Koyasu, S. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.004 · Cited by 53

Eosinophils in the Tumor Microenvironment

Mattei, F., Andreone, S., Marone, G., Gambardella, A. R., Loffredo, S., Varricchi, G., & Schiavoni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_1 · Cited by 53

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles

Arkhypov, I., Lasser, S., Petrova, V., Weber, R., Groth, C., Utikal, J. S., Altevogt, P., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176319 · Cited by 55

Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy

Zhang, H., Zhao, W., Li, X., & He, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315998 · Cited by 49

Eosinophils and Lung Cancer: From Bench to Bedside

Sibille, A., Corhay, J.-L., Louis, R. E., Ninane, V., Jérusalem, G., & Duysinx, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095066 · Cited by 48

Prognostic biomarkers of cutaneous melanoma

Ding, L., Gosh, A., Lee, D. J., Emri, G., Huss, W. J., Bogner, P. N., & Paragh, G. (2022) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12770 · Cited by 50

New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer

Holub, K., & Biete, A. (2018) · BMC Cancer · doi:10.1186/s12885-018-5131-x · Cited by 45

A Retrospective Analysis of Eosinophilia as a Predictive Marker of Response and Toxicity to Cancer Immunotherapy

Krishnan, T., Tomita, Y., & Roberts‐Thomson, R. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0070 · Cited by 40

Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy

Alves, A., Dias, M., Campainha, S., & Barroso, A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3525 · Cited by 41

Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review

Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 38

Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Vasaturo, A., Bagnall, C. J., Forsyth, R. G., Dufait, I., Tuyaerts, S., Riet, I. V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005141 · Cited by 37

Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer

Ghebeh, H., Elshenawy, M. A., Alsayed, A., & Al‐Tweigeri, T. (2022) · Immunotherapy · doi:10.2217/imt-2021-0149 · Cited by 37

Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis

Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34

Harnessing myeloid cells in cancer

Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35

Reinventing type 2 immunity in cancer

Wagner, M., Nishikawa, H., & Koyasu, S. (2025) · Nature · doi:10.1038/s41586-024-08194-2 · Cited by 36

Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse

Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Beaumecker, B., Bours, V., & Jérusalem, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1761176 · Cited by 31

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

Krückel, A., Moreira, A., Fröhlich, W., Schuler, G., & Heinzerling, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5384-z · Cited by 31

Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma

Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Carè, A., & Mattia, G. (2021) · Cancers · doi:10.3390/cancers13122875 · Cited by 36

Eosinophilia in cancer and its regulation by sex hormones

Artham, S., Chang, C., & McDonnell, D. P. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.11.002 · Cited by 29

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Takeuchi, E., Kondo, K., Okano, Y., Ichihara, S., Kunishige, M., Kadota, N., Machida, H., Hatakeyama, N., Naruse, K., Ogino, H., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15100 · Cited by 27

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment

Onesti, C. E., Josse, C., Poncin, A., Frères, P., Poulet, C., Bours, V., & Jérusalem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.26120 · Cited by 26

Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy

Goerig, N. L., Frey, B., Korn, K., Fleckenstein, B., Überla, K., Schmidt, M. A., Dörfler, A., Engelhorn, T., Eyüpoglu, I. Y., Rühle, P. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3195 · Cited by 25

Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy

Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24

Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study

Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 25

Hypereosinophilia in a Patient with Metastatic Non-Small-Cell Lung Cancer Treated with Antiprogrammed Cell Death 1 (anti-PD-1) Therapy

Lou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 23

Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single‐centre analysis

Gambichler, T., Brown, V., Steuke, A. ‐., Schmitz, L., Stockfleth, E., & Susok, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14629 · Cited by 22

CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis

Huang, Y., Wu, L., Sun, Y., Li, J., Mao, N., Yang, Y. A., Zhao, M., & Ren, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18215 · Cited by 22

Eosinophils and melanoma: Implications for immunotherapy

Robinson, I., Lucia, G. S., Li, A. R., Oberholtzer, N. P., Plante, J. G., Quinn, K. M., Reuben, D. Y., Mehrotra, S., & Valdebran, M. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13025 · Cited by 23

Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma

Tomsitz, D., Schlaak, M. S., Zierold, S., Pesch, G., Schulz, T. U., Müller, G., Zecha, C., French, L. E., & Heinzerling, L. (2022) · Cancers · doi:10.3390/cancers14133282 · Cited by 23

The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer

Ohkuma, R., Kubota, Y., Horiike, A., Ishiguro, T., Hirasawa, Y., Ariizumi, H., Watanabe, M., Onoue, R., Ando, K., Tsurutani, J., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001731 · Cited by 20

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 23

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 23

Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response

Toussaint, F., Hammon, M., Erdmann, M., Moreira, A., Kirchberger, M. C., Schuler, G., Schett, G., & Heinzerling, L. (2019) · Rheumatology · doi:10.1093/rheumatology/kez164 · Cited by 19

Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series

Nykaza, I. R., Moy, A. P., Dusza, S. W., Moskowitz, A. J., Iyer, G., Iqbal, A. N., Motzer, R. J., Ilson, D. H., O'Cearbhaill, R. E., Kazi, R., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf208 · Cited by 19

Pre‐treatment comorbidities, C‐reactive protein and eosinophil count, and immune‐related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities

Mehra, T., Dongre, K., Boesing, M., Frei, P., Suenderhauf, C., Zippelius, A., Leuppi, J. D., WICKI, A. N., & Leuppi-Taegtmeyer, A. B. (2023) · Cancer Medicine · doi:10.1002/cam4.5919 · Cited by 18

Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential

Jou, E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00146 · Cited by 19

Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report

Temiz, M. Z., Çolakerol, A., Ulus, I., Kılıç, E., Paslanmaz, F., Şahin, S., Yürük, E., Kandıralı, E., Semerciöz, A., & Müslümanoğlu, A. Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02673-x · Cited by 19

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer

Sibille, A., Henket, M. A., Corhay, J. L., Alfieri, R., Louis, R. E., & Duysinx, B. (2021) · Lung · doi:10.1007/s00408-021-00474-2 · Cited by 19

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma

Aicher, A., Sindrilaru, A., Crișan, D., Thaiss, W. M., Steinacker, J., Beer, M., Wiegel, T., Scharffetter‐­Kochanek, K., Beer, A. J., & Prasad, V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071466 · Cited by 19

Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota

Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 20

One-Tube Multicolor Flow Cytometry Assay (OTMA) for Comprehensive Immunophenotyping of Peripheral Blood

Donaubauer, A.-J., Rühle, P. F., Becker, I., Fietkau, R., Gaipl, U. S., & Frey, B. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_8 · Cited by 18

Innate Lymphoid Cells in Skin Homeostasis and Malignancy

Wagner, M., & Koyasu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758522 · Cited by 19

Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report

Occhipinti, M. A., Falcone, R., Onesti, C. E., & Marchetti, P. (2018) · Drug Safety - Case Reports · doi:10.1007/s40800-018-0078-z · Cited by 17

Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines

Sheng, L., Chen, X., Wang, Q., Lyu, S., & Li, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109966 · Cited by 17

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma

Wendlinger, S., Wohlfarth, J., Kreft, S., Siedel, C., Kilian, T., Dischinger, U., Heppt, M. V., Wistuba‐Hamprecht, K., Meier, F. E., Goebeler, M., et al. (2022) · Cancers · doi:10.3390/cancers14092294 · Cited by 19

Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth

Cederberg, R. A., Franks, S. E., Wadsworth, B. J., So, A., Decotret, L. R., Hall, M. G., Shi, R., Hughes, M. R., McNagny, K. M., & Bennewith, K. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841921 · Cited by 16

Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay

Donaubauer, A.-J., Becker, I., Rühle, P. F., Fietkau, R., Gaipl, U. S., & Frey, B. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.03.003 · Cited by 15

Tailoring precision immunotherapy: coming to a clinic soon?

Han, S., Shuen, T. W. H., Wang, W.-W., Nazim, E., & Toh, H. C. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000631 · Cited by 16

Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy

Wagner, N. B., Luttermann, F., Gassenmaier, M., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13248 · Cited by 15

Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion

Takeuchi, E., Okano, Y., Machida, H., Atagi, K., Kondou, Y., Kadota, N., Hatakeyama, N., Naruse, K., & Shinohara, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02994-5 · Cited by 15

Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy

Yang, X., Wang, L., Du, H., Lin, B., Yi, J., Wen, X., Geng, L., & Du, X. (2021) · Medicine · doi:10.1097/md.0000000000024328 · Cited by 14

α‐FAtE : A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Rossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34799 · Cited by 14

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Zhuang, T., Ravindranathan, D., Liu, Y., Martini, D. J., Brown, J. T., Nazha, B., Russler, G. A., Yantorni, L. B., Caulfield, S. E., Carthon, B. C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac236 · Cited by 15

The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC

Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13

Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters

Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 13

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature

Soto, F., Torre-Sada, L. F., Mott, F. E., Kim, S. T., Nurieva, R., Nagarajan, P., Guo, M., Shannon, V. R., Faiz, S. A., Casal, R. F., et al. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-30 · Cited by 11

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma

Willems, M., Scherpereel, A., Wasielewski, E., Raskin, J., Brossel, H., Fontaine, A., Grégoire, M., Halkin, L., Jamakhani, M., Heinen, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148798 · Cited by 11

Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)

Gambale, E., Maruzzo, M., Messina, C. G. M., Aquino, I. D. G., Vascotto, I. A., Rossi, V., Bimbatti, D., Cavasin, N., Messina, M., Mennitto, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102099 · Cited by 12

Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma

Kartolo, A., Holstead, R. G., Hopman, W. M., & Baetz, T. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0265 · Cited by 11

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors

Rogers, C. B. B., Zawislak, M. C., & Victoria Wong, P.-C. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.4.4 · Cited by 11

Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer

Ju, M., Fan, J., Zou, Y., Yu, M., Jiang, L., Wei, Q., Bi, J., Hu, B., Wang, L., Guan, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807840 · Cited by 10

Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma

Guardamagna, M., Berciano‐Guerrero, M., Lavado-Valenzuela, R., Auclin, É., Onieva-Zafra, J. L., Plaza-Andrades, I. J., Oliver, J., Garrido-Aranda, A., Pérez-Ruiz, E., Álvarez, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11054-2 · Cited by 10

Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma

Grüninger, J., Lehr, S., Meiß, F., Rafei-Shamsabadi, D. A., & Schauer, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613552 · Cited by 9

Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma

Chen, S., Zhang, L., Lin, H., Liang, Y., & Wang, Y. (2022) · Biomolecules · doi:10.3390/biom13010058 · Cited by 9

Eosinophils in metastatic melanoma

Proffer, S. L., Guo, R., Demer, A. M., & Peters, M. S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.08.001 · Cited by 9

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Moreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030210 · Cited by 9

Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region

Wu, Y., Yang, J., Qiao, X., Li, Y., Zhao, R., Lin, T., Li, X., & Wang, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1041140 · Cited by 8

Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma

Singh, N., Lubana, S. S., Constantinou, G., & Leaf, A. N. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/7492634 · Cited by 8

Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma

Şahin, G., Acar, C., Yüksel, H. Ç., Tünbekici, S., Açar, F. P., Çelebi, G., & Karaca, B. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04024-7 · Cited by 7

A tumor-associated endothelial signature score model in immunotherapy and prognosis across pan-cancers

Chen, S., Zhang, L., Huang, M., Liang, Y., & Wang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190660 · Cited by 7

Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study

Manger, I., Schmitt, C., Berking, C., French, L. E., Vera, J., & Heinzerling, L. M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13857-y · Cited by 6

A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma

Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 6

Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating

Georgescu, S. R., Mitran, C. I., Mitran, M. I., Matei, C., Constantin, C., Neagu, M. T., & Tampa, M. Ş. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091506 · Cited by 6

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand, C. L., Hunger, R. E., & Jafari, S. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366081 · Cited by 6

Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma

Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02962-8 · Cited by 6

Eosinophil ETosis and Cancer: Ultrastructural Evidence and Oncological Implications

Caruso, R. A., Caruso, V., & Rigoli, L. C. (2025) · Cancers · doi:10.3390/cancers17193250 · Cited by 7

The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study

Vacher, L., Bernadach, M., Molnar, I., Passildas, J., & Dubray‐Longeras, P. (2024) · Health Science Reports · doi:10.1002/hsr2.1825 · Cited by 4

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 23

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma

Krückel, A., Moreira, A., Fröhlich, W., Schuler, G., & Heinzerling, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5384-z · Cited by 31

Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma

Kartolo, A., Holstead, R. G., Hopman, W. M., & Baetz, T. D. (2020) · Immunotherapy · doi:10.2217/imt-2020-0265 · Cited by 11

Eosinophilia as a predictor of response to checkpoint inhibition in patients with metastatic melanoma.

Bridgman, T. (2021) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.57129/aeyk1627

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand, C. L., Hunger, R. E., & Jafari, S. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1366081 · Cited by 6